Evidence map›Paper›PMID 24957366›Full record

ArticleMetabolites2012

Mass spectrometry based lipidomics: an overview of technological platforms.

Harald C Köfeler, Alexander Fauland, Gerald N Rechberger, Martin Trötzmüller

Abstract read
In one paragraph

Article in Metabolites, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Decoding the Role of Lipid Metabolism and Membrane Dynamics in Melanoma.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Lipids as Emerging Biomarkers in Neurodegenerative Diseases.International journal of molecular sciences · 2023
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Early-stage mapping of macromolecular content in APPFrontiers in aging neuroscience · 2023
    Article
  19. Article
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Harald C KöfelerCore Facility for Mass Spectrometry, Medical University of Graz, Stiftingtalstrasse 24, 8010 Graz, Austria. harald.koefeler@medunigraz.at.
Alexander FaulandInstitute of Analytical Chemistry and Food Chemistry, Graz University of Technology, Stremayrgasse 9/II, 8010 Graz, Austria. alexander.fauland@tugraz.at.
Gerald N RechbergerDepartment for Molecular Biosciences, University of Graz, Humboldtstrasse 50/II, 8010 Graz, Austria. gerald.rechberger@uni-graz.at.
Martin TrötzmüllerCore Facility for Mass Spectrometry, Medical University of Graz, Stiftingtalstrasse 24, 8010 Graz, Austria. martin.troetzmueller@medunigraz.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One decade after the genomic and the proteomic life science revolution, new 'omics' fields are emerging. The metabolome encompasses the entity of small molecules-Most often end products of a catalytic process regulated by genes and proteins-with the lipidome being its fat soluble subdivision. Within recent years, lipids are more and more regarded not only as energy storage compounds but also as interactive players in various cellular regulation cycles and thus attain rising interest in the bio-medical community. The field of lipidomics is, on one hand, fuelled by analytical technology advances, particularly mass spectrometry and chromatography, but on the other hand new biological questions also drive analytical technology developments. Compared to fairly standardized genomic or proteomic high-throughput protocols, the high degree of molecular heterogeneity adds a special analytical challenge to lipidomic analysis. In this review, we will take a closer look at various mass spectrometric platforms for lipidomic analysis. We will focus on the advantages and limitations of various experimental setups like 'shotgun lipidomics', liquid chromatography-Mass spectrometry (LC-MS) and matrix assisted laser desorption ionization-time of flight (MALDI-TOF) based approaches. We will also examine available software packages for data analysis, which nowadays is in fact the rate limiting step for most 'omics' workflows.

Identifiers

PMID24957366
PMCPMC3901195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.